Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 17/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27181382 | 1.00 | PSMB5 (0.42) | PSMB5PSMB8MEN1LMNATSHR | |
| SCHEMBL25400906 | 0.85 | PSMB5 (0.46) | PSMB5PSMB8PSMB1PSMB2 | |
| SCHEMBL25400915 | 0.85 | PSMB5 (0.46) | PSMB5PSMB8PSMB1PSMB2 | |
| SCHEMBL25400733 | 0.85 | PSMB5 (0.57) | PSMB5PSMB8PSMB1PSMB2 | |
| SCHEMBL25400738 | 0.85 | PSMB5 (0.57) | PSMB5PSMB8PSMB1PSMB2 | |
| SCHEMBL25399678 | 0.84 | PSMB5 (0.56) | PSMB5PSMB8 | |
| SCHEMBL25399672 | 0.84 | PSMB5 (0.56) | PSMB5PSMB8 | |
| SCHEMBL25401858 | 0.81 | PSMB5 (0.51) | PSMB5PSMB8PSMB1PSMB2 | |
| SCHEMBL25401854 | 0.81 | PSMB5 (0.51) | PSMB5PSMB8PSMB1PSMB2 | |
| SCHEMBL25399858 | 0.81 | CASP1 (0.43) | PSMB5PSMB8TSHRPSMB1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | PSMB5 10/4885PSMB8 5/4885MEN1 800/4885 |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | PSMB11, PSMB1, BACH1 | PSMB5 7/4885PSMB8 28/4885MEN1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.